Cumberland Pharmaceuticals Inc.
Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor Antagonists

Abstract:

The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A.sub.2 receptor antagonist.